Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. Show more

Location: Wagistrasse 14, Schlieren, 8952, Switzerland | Website: https://www.molecularpartners.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

133.7M

52 Wk Range

$3.36 - $12.22

Previous Close

$3.55

Open

$3.59

Volume

497

Day Range

$3.59 - $3.59

Enterprise Value

-5.072M

Cash

149.4M

Avg Qtr Burn

-14.81M

Insider Ownership

0.00%

Institutional Own.

9.72%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.